Anti-DGCR6L Polyclonal Antibody for WB, ELISA - Q9BY27

Core Product Specifications and Parameters

Biological Background: DGCR6L Function and Localization

• DGCR6L (DiGeorge syndrome critical region 6-like protein) is a nuclear protein that may play a role in neural crest cell migration into the third and fourth pharyngeal pouches.
• It is widely expressed in fetal and adult tissues, with highest expression in liver, heart, and skeletal muscle, and lower levels in pancreas and placenta; weak expression in brain.
• Subcellular localization is the nucleus.
• The protein contains a coiled coil domain and is a phosphoprotein identified through proteomics.
• The predicted molecular weight is approximately 25 kDa, consistent with the antibody's detection band.
• The DGCR6L gene lies within the DiGeorge syndrome critical region, implicating it in developmental disorders.

Experimental Guidance and Technical Tips

• The immunogen consists of the full-length N-terminal region (amino acids 1–220); consider that the antibody may recognize both native and denatured forms of DGCR6L.
• For Western blot, a band at ~25 kDa is expected; include appropriate positive controls from human, mouse, or rat lysates.
• For ELISA, validate the antibody’s performance with the specific coating antigen and sample matrix.
• Given the cross-reactivity with mouse and rat, verify specificity in these species using knockout or knockdown controls where available.
• The antibody is supplied as a polyclonal preparation; lot-to-lot consistency should be assessed for critical quantitative assays.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This DGCR6L antibody supports investigations into neural crest biology and DiGeorge syndrome, areas where reliable detection reagents are essential. Through our extensive supply network, we offer validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and rare target sourcing to accelerate your assay development and production scaling.